Team Leader
US Food and Drug Administration
Dr. Salaheldin Hamed is currently a Team Lead in the Division of Cancer Pharmacology in the Office of Clinical Pharmacology at the FDA. Dr. Hamed received his bachelor’s and Doctorate degrees in Biomedical Engineering from Rutgers University.
Dr. Hamed's thesis work included mathematical modeling to characterize the responses of cancer cells to chemotherapy and to understand how cells develop acquired resistance to chemotherapy. Dr. Hamed completed his postdoctoral training at the University at Buffalo in Pharmacokinetic and Pharmacodynamic modeling of chemotherapeutic drugs.
Dr. Hamed joined the FDA in 2012 as a research fellow in the Division of Applied Regulatory Sciences. He worked on the PKPD modeling of narrow therapeutic index drugs and several other projects. He joined the Division of Cancer Pharmacology in the Office of Clinical Pharmacology in 2015. In addition to his review duties, Dr. Hamed has been serving the Acting Biosimilars Lead in the Division of Cancer Pharmacology.
Hi Cancer, We Come Bearing Gifts, Antibody-Drug Conjugate
Thursday, March 23, 2023
9:30 AM – 10:30 AM EDT